在德拉维特综合征中通过迷走神经刺激减少长期的发作
Sunanjay Bajaj1, Alina Ivaniuk2, Tobias Bruenger1
1Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Developmental medicine and child neurology
|January 12, 2026
概括
神经刺激 (VNS) 显著减少了德拉维特综合征的长期发作. 最佳VNS参数,而不是抗发作药物,预测了发作减少,提供了持久的管理.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 医疗技术 医疗技术 医学技术
背景情况:
- 德拉维特综合征是一种严重的遗传性,具有具有挑战性的抗治疗能力.
- 在德拉维特综合征中,迷走神经刺激 (VNS) 的长期疗效数据有限.
研究的目的:
- 为了评估VNS在Dravet综合征患者的长期有效性.
- 确定影响VNS治疗反应的因素.
主要方法:
- 对15名Dravet综合征患者进行了回顾性队列研究,这些患者接受了VNS植入.
- 在植入后10年内评估的发作频率.
- 线性混合效应回归分析了抗发作药物 (ASM) 和VNS参数效应.
主要成果:
- 93.3%的患者在12个月后实现了≥50%的发作减少;在10年后达到86.7%.
- 发作减少是独立于ASM的使用.
- 在VNS工作周期中,预测显著减少了发作;小不良事件在13.3%.
结论:
- 在德拉维特综合征中,VNS提供了持久的发作减轻,无论ASM调整如何.
- 早期VNS启动和参数优化对于管理这种综合征至关重要.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
804
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


